Incomplete success of angioinhibitor therapy in cancer: Estimation of contribution of pro-angiogenic activity of patient thyroid hormone

Paul J. Davis, Murat Yalcin, Hung Yun Lin, Heng Yuan Tang, Aleck Hercbergs, John T. Leith, Faith B. Davis, Mary K. Luidens, Shaker A. Mousa

研究成果: 雜誌貢獻文章同行評審

4 引文 斯高帕斯(Scopus)

摘要

Despite the obvious promise of the strategy, pharmaceutical angioinhibition has had variable success in clinical cancer management. Thyroid hormone is a potent pro-angiogenic factor. Endogenous circulating levels of proangiogenic thyroid hormone in cancer patients treated with anti-angiogenic drugs may contribute to host resistance to angioinhibition and explain, at least in part, the variable cancer chemotherapeutic responses obtained with anti-angiogenic agents. The chick chorioallantoic membrane (CAM) angiogenesis assay accepts human tumor xenografts and is a system in which individual patient blood samples can be tested in xenograft vasculature for anti-angiogenic content-including thyroid hormone-in the presence of angioinhibitory drug dose escalation. The assay may also be used to screen individual patient tumor biopsy xenografts for susceptibility to angioinhibition.
原文英語
頁(從 - 到)441-445
頁數5
期刊Journal of Cancer Science and Therapy
5
發行號12
DOIs
出版狀態已發佈 - 2013

ASJC Scopus subject areas

  • 癌症研究
  • 腫瘤科

指紋

深入研究「Incomplete success of angioinhibitor therapy in cancer: Estimation of contribution of pro-angiogenic activity of patient thyroid hormone」主題。共同形成了獨特的指紋。

引用此